Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 211.00B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 13.01 |
| Forward PE | 10.83 |
| Dividend | 2.91 (3.42%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 3,399 |
| Average Volume | 4,383 |
| Open | 81.10 |
| Previous Close | 81.90 |
| Day's Range | 81.10 - 85.10 |
| 52-Week Range | 65.50 - 99.40 |
| Beta | 0.32 |
| RSI | 75.94 |
| Earnings Date | Oct 30, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Merck (MRK) Gains FDA Approval for Keytruda in Bladder Cancer Treatment
Merck (MRK) Gains FDA Approval for Keytruda in Bladder Cancer Treatment
Merck gets FDA nod for Keytruda and Padcev combo in bladder cancer treatment
Merck (MRK) Gains FDA Nod for Keytruda Combination in Bladder Cancer
Merck (MRK) Gains FDA Nod for Keytruda Combination in Bladder Cancer
FDA Approves KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembr...
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrol...
Noteworthy Friday Option Activity: MRK, CAPR, IE
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Merck & Co Inc (Symbol: MRK), where a total volume of 95,066 contracts has been tr...
Why Are Shares of Merck Up Today?
Shares of Merck & Company, Inc. (NASDAQ: MRK) are trading higher the FDA approved pembrolizumab with enfortumab vedotin-ejfv for muscle-invasive bladder cancer. MRK shares are powering higher on stro...
FDA Approves Merck's (MRK) Keytruda for Bladder Cancer Treatment
FDA Approves Merck's (MRK) Keytruda for Bladder Cancer Treatment
Merck Keytruda formulations approved in U.S. for bladder cancer
Merck (MRK) stock is in focus as the FDA approves its Keytruda versions with Pfizer (PFE) and Astellas' (ALPMF) Padcev for bladder cancer. Read more here.
Retirement: 2 Healthcare Giants To Buy At Discounted Prices
Merck and Elevance Health stocks are top dividend growth picks with solid yields and attractive valuations. Click here to learn more about MRK and ELV.
The Zacks Analyst Blog Highlights Visa, Merck, Southern Company, Community Bancorp and Comstock
V benefits from rising cross-border volumes and strong digital payments momentum as analysts spotlight broad performance drivers across key sectors.
Top Analyst Reports for Visa, Merck & Southern Company
Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory pressures.
Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield
Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the c...
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
The pharmaceutical giant's post-Keytruda plans continue to take shape.
The Northeast Science & Technology Center Advances Next Phase of Campus Enhancements
The creation and renovation of over 75,000 SF of amenity and common space to support an ecosystem of research and innovation for current and future tenants KENILWORTH, N.J. , Nov. 20, 2025 /PRNewswire...
Merck's $3 Billion AI Gamble: Inside the Bold Bet to Crack Parkinson's
Merck's $3 Billion AI Gamble: Inside the Bold Bet to Crack Parkinson's
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and the...
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in ...
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in a...
Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025
In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here.
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
Merck (MRK) Gains EU Approval for Subcutaneous Keytruda
Merck (MRK) Gains EU Approval for Subcutaneous Keytruda